Comparative Pharmacology
Head-to-head clinical analysis: BACTROBAN versus CENTANY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACTROBAN versus CENTANY.
BACTROBAN vs CENTANY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to isoleucyl-tRNA synthetase, inhibiting bacterial protein synthesis.
Mupirocin binds to isoleucyl-tRNA synthetase, inhibiting bacterial protein synthesis.
Mupirocin (Bactroban) 2% ointment or cream applied topically to affected area three times daily for 5 to 14 days. For intranasal use: 0.5 g of 2% ointment applied to each nostril twice daily for 5 days.
Apply a thin layer to affected area twice daily for 10 days. For perioral dermatitis, apply once daily.
None Documented
None Documented
Terminal elimination half-life: 1-1.5 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours in end-stage renal disease)
8-10 minutes in serum; prolonged to 15-20 minutes in patients with renal impairment. Clinical context: Rapidly cleared, infrequent dosing intervals (e.g., every 20 minutes during procedure).
Renal (90-95% unchanged), with minor biliary/fecal elimination (<5%)
Primarily excreted unchanged in urine via glomerular filtration and tubular secretion (85-90% renal); minor biliary/fecal elimination (<5%).
Category C
Category C
Topical Antibiotic
Topical Antibiotic